What Will Happen to Avenue Therapeutics, Inc. (ATXI) Next? The Stock Just Increased A Lot

March 14, 2018 - By Adrian Erickson

The stock of Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a huge mover today! The stock increased 14.32% or $0.68 during the last trading session, reaching $5.43. About 95,235 shares traded or 227.38% up from the average. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 5 months positive chart setup for the $55.74M company. It was reported on Mar, 14 by Barchart.com. We have $5.65 PT which if reached, will make NASDAQ:ATXI worth $2.23M more.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Globenewswire.com which released: “Avenue Therapeutics Receives Notice of Allowance for a New Patent Application …” on May 19, 2017, also Globenewswire.com with their article: “Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial …” published on January 02, 2018, Reuters.com published: “BRIEF-Avenue Therapeutics ic files for IPO of up to $50 mln” on May 22, 2017. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Globenewswire.com and their article: “Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 …” published on September 27, 2017 as well as Globenewswire.com‘s news article titled: “Avenue Therapeutics, Inc. (Nasdaq: ATXI) to Ring The Nasdaq Stock Market …” with publication date: February 09, 2018.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $55.74 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: